An open-label study has found data that could support the use of ABX464 as a treatment for moderate to severe ulcerative colitis (UC).  Investigators presented information from the ABX464-102 phase 2a study, which found that almost all patients demonstrated clinical response and nearly half were in clinical remission, at Digestive Disease Week 2019 in San Diego, CA